Edition:
United Kingdom

ACADIA Pharmaceuticals Inc (ACAD.OQ)

ACAD.OQ on NASDAQ Stock Exchange Global Select Market

18.57USD
11 Dec 2018
Change (% chg)

$-0.21 (-1.12%)
Prev Close
$18.78
Open
$19.06
Day's High
$19.11
Day's Low
$18.36
Volume
307,614
Avg. Vol
872,864
52-wk High
$32.99
52-wk Low
$12.80

Latest Key Developments (Source: Significant Developments)

Acadia Pharmaceuticals Prices Public Offering Of Common Stock
Wednesday, 28 Nov 2018 

Nov 28 (Reuters) - ACADIA Pharmaceuticals Inc ::ACADIA PHARMACEUTICALS PRICES PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 16.2 MILLION COMMON SHARES PRICED AT $17.00PER SHARE.GROSS PROCEEDS FROM OFFERING TO CO EXPECTED TO BE ABOUT $275.0 MILLION.OFFERING IS EXPECTED TO CLOSE ON NOVEMBER 30, 2018.  Full Article

Acadia Pharmaceuticals Files For Potential Stock Shelf Offering
Monday, 26 Nov 2018 

Nov 26 (Reuters) - ACADIA Pharmaceuticals Inc ::ACADIA PHARMACEUTICALS INC FILES FOR POTENTIAL STOCK SHELF OFFERING; SIZE NOT DISCLOSED .  Full Article

Acadia Announces Positive Top-Line Results From Phase 2 Pimavanserin Trial
Wednesday, 31 Oct 2018 

Oct 31 (Reuters) - ACADIA Pharmaceuticals Inc ::ACADIA PHARMACEUTICALS ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 2 CLARITY TRIAL OF PIMAVANSERIN FOR ADJUNCTIVE TREATMENT IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER (MDD).ACADIA PHARMACEUTICALS INC - PIMAVANSERIN MET PRIMARY ENDPOINT.ACADIA PHARMACEUTICALS INC - PIMAVANSERIN MET KEY SECONDARY ENDPOINT.ACADIA PHARMACEUTICALS INC - TO INITIATE PHASE 3 PROGRAM IN ADJUNCTIVE MDD IN 1H 2019.ACADIA - POSITIVE RESULTS ALSO OBSERVED ON SEVEN ADDITIONAL SECONDARY ENDPOINTS.  Full Article

Acadia Pharmaceuticals Announces Executive Leadership Change
Monday, 29 Oct 2018 

Oct 29 (Reuters) - ACADIA Pharmaceuticals Inc ::ACADIA PHARMACEUTICALS ANNOUNCES EXECUTIVE LEADERSHIP CHANGE.ACADIA PHARMACEUTICALS INC - TODD S. YOUNG, EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER, WILL BE LEAVING.ACADIA PHARMACEUTICALS INC - ELENA RIDLOFF, CFA, SENIOR VICE PRESIDENT, INVESTOR RELATIONS WILL SERVE AS COMPANY'S INTERIM CHIEF FINANCIAL OFFICER..ACADIA PHARMACEUTICALS INC - TODD YOUNG, CHIEF FINANCIAL OFFICER, WILL BE LEAVING EFFECTIVE OCTOBER 31, 2018 TO JOIN ANOTHER HEALTHCARE COMPANY.  Full Article

FDA Says Finds No New Or Unexpected Safety Risks Associated With Nuplazid
Thursday, 20 Sep 2018 

Sept 20 (Reuters) - U.S. Food and Drug Administration::FDA - FINDS NO NEW/UNEXPECTED SAFETY RISKS ASSOCIATED WITH NUPLAZID, A MEDICATION TO TREAT HALLUCINATIONS, DELUSIONS OF PARKINSON’S DISEASE PSYCHOSIS.FDA- CONCLUSION REMAINS UNCHANGED THAT NUPLAZID'S BENEFITS OUTWEIGH ITS RISKS FOR PATIENTS WITH HALLUCINATIONS&DELUSIONS OF PARKINSON’S DISEASE PSYCHOSIS.FDA - RISK OF QT PROLONGATION AND SERIOUS ARRHYTHMIA ASSOCIATED WITH NUPLAZID IS NOTED IN WARNINGS AND PRECAUTIONS SECTION OF DRUG LABEL.FDA - SOME POTENTIALLY CONCERNING PRESCRIBING PATTERNS WERE OBSERVED ASSOCIATED WITH NUPLAZID.  Full Article

Acadia Pharmaceuticals Q2 Loss Per Share $0.51
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - ACADIA Pharmaceuticals Inc ::ACADIA PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.51.Q2 SALES $57.1 MILLION VERSUS I/B/E/S VIEW $58.6 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.45 -- THOMSON REUTERS I/B/E/S.LOWERING ITS 2018 NUPLAZID NET SALES GUIDANCE TO BE BETWEEN $210 MILLION AND $225 MILLION.FOR Q3 OF 2018, ACADIA EXPECTS NUPLAZID NET SALES TO BE BETWEEN $52 MILLION AND $59 MILLION.ACADIA PHARMACEUTICALS - LOWERING GUIDANCE FOR ITS YEAR END 2018 CASH, CASH EQUIVALENTS AND INVESTMENT SECURITIES TO BE BETWEEN $155 MILLION TO $170 MILLION.  Full Article

Acadia Pharmaceuticals posts Q3 loss of $0.53 per share
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Acadia Pharmaceuticals Inc :Acadia Pharmaceuticals reports third quarter 2017 financial results.Q3 loss per share $0.53.Q3 sales $35.6 million versus I/B/E/S view $32 million.Sees FY 2017 sales $124 million to $127 million.Q3 earnings per share view $-0.62 -- Thomson Reuters I/B/E/S.  Full Article